Innoviva (INVA) EBT Margin Growth (5y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.19 Mn |
| Dec 31, 2025 | -1.93 Mn |
| Sep 30, 2025 | 3,382.00 |
| Jun 30, 2025 | -7,722.00 |
| Mar 31, 2025 | -16,414.00 |
| Dec 31, 2024 | -94,585.00 |
| Sep 30, 2024 | -7,996.00 |
| Jun 30, 2024 | -12,744.00 |
| Mar 31, 2024 | 458,328.00 |
| Dec 31, 2023 | -52,209.00 |
| Sep 30, 2023 | 4,646.00 |
| Jun 30, 2023 | 50,795.00 |
| Mar 31, 2023 | 511,044.00 |
| Dec 31, 2022 | -102,628.00 |
| Sep 30, 2022 | 2.20 Mn |
| Jun 30, 2022 | 102,707.00 |
| Mar 31, 2022 | 357,648.00 |
| Dec 31, 2021 | -66,847.00 |
| Sep 30, 2021 | 8,090.00 |
| Jun 30, 2021 | 1.16 Mn |
| Mar 31, 2021 | 1.21 Mn |
| Dec 31, 2020 | 1.80 Mn |
| Sep 30, 2020 | 9,072.00 |
| Jun 30, 2020 | 22,292.00 |
| Mar 31, 2020 | 27,528.00 |
| Dec 31, 2019 | 31,125.00 |
| Sep 30, 2019 | 224,467.00 |
| Jun 30, 2019 | 221,585.00 |
| Mar 31, 2019 | 216,255.00 |
| Dec 31, 2018 | 69,539.00 |
| Sep 30, 2018 | 235,941.00 |
| Jun 30, 2018 | 20,096.00 |
| Mar 31, 2018 | 277,636.00 |
| Dec 31, 2017 | 864.00 |
| Sep 30, 2017 | 249,597.00 |
| Jun 30, 2017 | 715,887.00 |
| Mar 31, 2017 | -2,576.00 |
| Dec 31, 2016 | 74,711.00 |
| Sep 30, 2016 | 52,119.00 |
| Jun 30, 2016 | 43,166.00 |
| Mar 31, 2016 | 37,880.00 |